Pharmaceuticals · BIOS
Pharma - Formulators
from 423 today
We retain a Buy rating with a revised PT of Rs. 498 on account of refinancing-led margin visibility, strong Q1 numbers, and an expected strong H2 launch pipeline.
Biocon delivered in-line revenue for the quarter, with EBITDA/PAT lower than expected. Biosimilars and generics led robust revenue growth, while Syngene dragged overall performance in 1QFY27 due to lower offtake from certain key customers.
Biocon reported Q1FY27 revenue of Rs 4,336 Cr, up 10% YoY, driven by strong growth in Biosimilars and Generics, though partially offset by a decline in the Services segment. Operating leverage, stable EBITDA margins, and lower interest costs supported a 51.6% YoY increase in PAT to Rs 135 Cr.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
